Pharmacists in Leechburg, Pennsylvania


13 Pharmacists found in Leechburg
female pharmacist

Dr. Abbie L. Mcgowan, PHARMD


Pharmacist
451 Hyde Park Rd, Leechburg, PA 15656
724-845-1880     724-845-3471

male pharmacist

Alexander J Micklow, R.PH.


Pharmacist
165 Market St, Leechburg, PA 15656
724-842-1771     724-845-7897

female pharmacist

Dr. Amy Cignetti, PHARM.D


Pharmacist
41 Towne Center Dr, Leechburg, PA 15656
724-845-1077    



male pharmacist

James Ruperto


Pharmacist
41 Towne Center Dr, Leechburg, PA 15656
724-845-1077    

male pharmacist

Jared Bowser


Pharmacist
41 Towne Center Dr, Leechburg, PA 15656
724-845-1077    

male pharmacist

Joseph Troyan


Pharmacist
117a 3rd St, Leechburg, PA 15656
724-845-7501     724-845-7818

female pharmacist

Mrs. Karen Gayle Chobirko, RPH


Pharmacist
451 Hyde Park Rd, Leechburg, PA 15656
724-845-1880     724-845-3471

female pharmacist

Ms. Kimberly M Davis, RPH


Pharmacist
41 Towne Center Dr, Leechburg, PA 15656
724-845-1077    

female pharmacist

Dr. Kris Ridenour, PHARMD


Pharmacist
41 Towne Center Dr, Leechburg, PA 15656
724-845-1077    

female pharmacist

Maggie Petit


Pharmacist
41 Towne Center Dr, Leechburg, PA 15656
724-845-1077    

female pharmacist

Rachael Mary Moustaader, PHARMD, BCPS, TTS


Pharmacist
62 Greenbriar Dr Ste 1, Leechburg, PA 15656
724-845-7765     724-845-8418

male pharmacist

Mr. Richard Joseph Dodek


Pharmacist
111 2nd St, Suite 200, Leechburg, PA 15656
724-845-1184    

male pharmacist

Zachary Scott


Pharmacist
41 Towne Center Dr, Leechburg, PA 15656
724-845-1077     724-845-4355


Type of Pharmacists:
Psychiatric Pharmacist: A licensed pharmacist who has demonstrated specialized knowledge and skill in optimizing care of patients with psychiatric illness by assessing and monitoring patients, recognizing drug-induced problems, and recommending appropriate treatment plans.
Oncology Pharmacist: A licensed pharmacist who has demonstrated specialized knowledge and skill in developing, recommending, implementing, monitoring, and modifying pharmacotherapeutic plans to optimize outcomes in patients with malignant diseases.